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Abstract
Purpose The minimally important difference (MID)
represents the smallest change in score on patient-reported
outcome measures that is relevant to patients. The aim of
this study was to introduce the MID for the Vascular
Quality of Life Questionnaire (VascuQol) and the walking
impairment questionnaire (WIQ) for patients with inter-
mittent claudication (IC).
Methods In this multicenter study, we recruited 294 pa-
tients with IC between July and October 2012. Patients
completed the VascuQol, with scores ranging from 1 to 7
(worst to best), and theWIQ, with scores ranging from 0 to 1
(worst to best) at first visit and after 4 months follow-up. In
addition, patients answered an anchor-question rating their
health status compared to baseline, as being improved, un-
changed, or deteriorated. The MID for improvement and
deterioration was calculated by an anchor-based approach,
and determined with the upper and lower limits of the 95 %
confidence interval of the mean change of the group who
had not changed according to the anchor-question.
Results For the MID analyses of the VascuQol and WIQ,
163 and 134 patients were included, respectively. The MID
values for the VascuQol (mean baseline score 4.25) were 0.87
for improvement and 0.23 for deterioration. For the WIQ
(mean baseline score 0.39), we foundMID values of 0.11 and
-0.03 for improvement and deterioration, respectively.
Conclusion In this study, we calculated the MID for the
VascuQol and the WIQ. Applying these MID facilitates
better interpretation of treatment outcomes and can help to
set treatment goals for individual care.
Keywords Claudication  Clinical practice 
Biostatistics
Introduction
Since the treatment of patients with intermittent claudica-
tion (IC) is primarily aimed at improving their walking
ability and health-related quality of life (HRQL), it is
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essential that these endpoints are measured when evaluat-
ing treatment. Walking ability is a part of a patient’s
functional status (FS), and is frequently assessed using a
treadmill test. However, treadmill tests do not correlate
well with real-life walking distances, and are not an ade-
quate reflection of the patient’s perceived walking im-
pairment.[1, 2] Therefore, FS can better be assessed using
patient-reported outcome measures (PROMs), such as the
walking impairment questionnaire (WIQ) [3]. HRQL can
be defined as the aspects of quality of life that relate
specifically to a person’s health [4]. The Vascular Quality
of Life Questionnaire (VascuQol) is an example of a dis-
ease-specific HRQL PROM for patients with peripheral
artery disease (PAD) [5].
The importance of PROMs to evaluate treatment out-
comes has been recognized by the vascular community,
and they are used as endpoints in many clinical trials [6–9].
The next step will be to use PROMs in routine clinical
practice. However, the interpretation of changes in PROM
scores may be difficult when it is unknown how much
change is actually considered relevant by patients. A sta-
tistically significant mean change in score after treatment in
a sample doesn’t necessarily imply that an individual pa-
tient experiences a clinically meaningful change in his or
her HRQL or FS.
The minimally important difference (MID) represents
‘the smallest change in score in the construct to be mea-
sured which patients perceive as important’ [10]. The MID
can aid to better appreciate trial results and individual
treatment results, can be calculated for all available
PROMs and is relevant in all patient populations. This is
illustrated in the following example. In a (fictional) clinical
trial a PROM is used with a score range from 0 to 100. A
statistically significant change in mean score for the patient
sample from 25 to 33 was found, but it is unknown if this
change is relevant to an individual patient. If, however, the
MID for that PROM was known to be ?10 points on the
scale, it would be immediately clear that an individual
patient would have to improve from a baseline score of 25
to at least 35 for the improvement to be clinically relevant.
The current study aims to introduce the concept of the
MID for the VascuQol and the WIQ in patients with IC.
This study was specifically not aimed at determining the
effect of different treatment modalities.
Methods
Patients
The institutional review board (IRB) of the Academic
Medical Center decided that this study met the criteria for
exemption from IRB approval.
We used the patient sample of a prospective pilot study
to determine the feasibility of PROMs as indicators of
quality of care for patients with PAD. This study was
conducted in cooperation with a Dutch health insurance
company.
Patients were enrolled from July 2012 until October
2012 in nine hospitals in the Netherlands. Patients were
eligible if they presented at the vascular surgery outpatient
clinic with complaints of IC due to PAD and if they had not
visited the outpatient clinic for symptomatic PAD in the
previous year. Other inclusion criteria were sufficient
knowledge of the Dutch language, an independent living
situation, absence of psychiatric disorders, and the ability
to communicate with the researchers.
Treatment
As recommended by national guidelines, first line treat-
ment was supervised exercise therapy (SET) in most pa-
tients [11]. Depending on physician and patient preferences
percutaneous transluminal angioplasty (PTA) was some-
times used as primary treatment, and a few patients were
treated with surgical revascularization. SET is only reim-
bursed by the Dutch health insurance when patients have
additional insurance. Therefore in some patients treatment
consisted of optimal medical therapy (OMT) (antiplatelet
drug and a statin, advice to walk, and change lifestyle).
Data Collection
In each centre, a local investigator was responsible for the
execution of the study and data collection at baseline and at
3–4 months follow-up. Patient characteristics and ques-
tionnaires were sent to an independent trusted party (ITP)
for further data linking and processing.
Data on smoking history, diabetes, pulmonary and
cardiac diseases, renal function, previous vascular inter-
ventions (PTA or surgery), ankle brachial index (ABI),
and number of affected legs were recorded at first visit in
a pre-specified database. At follow-up, it was also
recorded if a patient had received OMT or SET. No data
on age and gender were recorded in this database, since
these were retrieved when the ITP linked treatment codes
(conservative, PTA or surgery) in the Dutch insurance
billing system to patients in each hospital’s patient ad-
ministration. However, because unblinding was impossible
due to privacy reasons, it was impossible for the ITP to
retrieve data on age and gender if no treatment code was
listed. If no treatment code was listed, we used the data on
treatment modality recorded by the local investigator at
follow-up.
PROMs were handed out at the outpatient clinic or sent
by mail. Patients returned the PROMs by mail to the local
A. P. Conijn et al.: MID for PROM Interpretation 1113
123
investigator. When necessary, patients were contacted by
telephone to remind them and help fill in the PROM.
Only patients with available data on age and gender and
a resting ABI\0.9 were analysed in the present study to
ensure that the patient sample in the MID analysis had a
proven diagnosis of IC due to PAD. Baseline characteris-
tics and PROM scores of patients included and excluded
from the MID analysis were compared.
PROMs
The VascuQol is a disease-specific HRQL PROM, devel-
oped for patients with IC and critical limb ischemia [5]. It
consists of five subscales (pain, symptoms, activities,
emotional, and social) with 25 items in total. Each item is
rated on a 7-point rating scale, with 1 representing the
worst and 7 the best score. A total score, also ranging from
1 to 7, is calculated by dividing the sum of all items by 25.
The VascuQol has been validated in Dutch [12, 13].
The WIQ is a PROM to rate walking impairment and
consists of a speed, distance, and stairclimbing subscale
with 14 items in total [3]. Patients rate their perceived
difficulty of each item on a 5 point Likert scale. For ex-
ample, patients are asked to assign a degree of difficulty
with which they can walk 100 meters, with answers rang-
ing from ‘no problems’ to ‘impossible’. Each item is
weighted based on its difficulty. Subscale scores are cal-
culated by adding the weighted scores, and dividing this by
the maximum score so that each score ranges from 0 to 1,
with lower scores indicating a higher level of impairment.
An overall score is calculated as the mean of the three
subscale scores. The WIQ has also been validated in Dutch
[14, 15].
In addition to the PROMs, at follow-up patients filled in
the following anchor-question: ‘Has your condition chan-
ged in the past three months?’ with the following response
options: (a) improved, (b) unchanged, and (c) deteriorated.
Imputation of Missing Items
Imputation of the VascuQol subscales took place if at least
50 % of the subscale was filled in. Missing values were
imputed with the mean value of all the filled-in questions if
this condition was satisfied, and under the assumption of
‘‘completely missing at random’’.
When items were missing for the WIQ, we calculated a
best- and worst-case scenario. We hereby took into account
the questions the patients did fill in, and assumed that pa-
tients could never score higher on a harder task and never
lower on an easier task. If the best- and worst-case scenario
scores were no more than 0.25 points apart, we used the
mean of these two values as the total WIQ score.
Analysis
For the MID analysis, we used an anchor-based approach.
Anchor-based approaches determine the MID by compar-
ing PROMs to other measures or phenomena that have
clinical relevance [16]. Revicki et al. suggested that the
MID should be based on an anchor that has a correlation
C0.3 with the PROM [17]. Therefore, Pearson correlation
coefficients were calculated between the change in PROM
scores and the anchor-question. The upper and lower limit
of the 95 % confidence interval (CI) of the mean change of
the group who indicated on the anchor-question that their
situation had not changed after treatment represent the
MID for improvement and deterioration, respectively.
Differences in baseline characteristics and PROM scores
were determined with a student’s t-test for continuous
variables, and with a Chi-square or Fisher’s exact test
where appropriate for categorical variables. All analyses
were performed using SAS enterprise guide version 5.1;
SAS institute, Cary, NC, USA.
Results
A total of 294 patients with IC were included in the pilot
study. The VascuQol was sufficiently completed twice by
223 patients, the WIQ by 184 patients. After exclusion of
patients with unknown age, gender, and resting ABI[0.9
there were 163 patients who were suitable for the MID ana-
lysis of the VascuQol, and 134 for the WIQ. Baseline char-
acteristics of both the patients included and excluded from
the analysis are shown in Table 1. All baseline characteristics
and scores on PROMs were comparable for included and
excluded patients, except for the ABI. Missing items for both
PROMs are presented in Table S2 (online only).
Calculation of the MID for the VascuQol
Table 2 shows that the mean improvement in VascuQol
summary score was 0.83. The correlation between the an-
chor-question and the VascuQol was 0.47, thus meeting the
criteria of Revicki [17].
The MIDs calculated by the anchor-based approach
were 0.23 and 0.87, for deterioration and improvement,
respectively (Table 2). This means that patients with an
increase of C0.87 compared to their baseline score have
improved in a clinically relevant way. For deterioration, we
found an MID of 0.23. While one might expect a negative
MID value for deterioration, the MID value found here
indicates that an increase in VascuQol summary score of
less than 0.23 points is actually experienced as deteriora-
tion by patients.
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Table 1 Baseline characteristics
Baseline characteristics Total population
(n = 294)
VascuQol
(n = 163)
WIQ
(n = 134)
Excluded patients
VascuQol (n = 131)
Excluded patients
WIQ
(n = 160)
Age (years, SD) 66.5 (± 10.4)
(n = 271)
66.6 (±10.3) 65.9 (±10.1) 66.5 (±10.6) (n = 108) 67.1
(±10.7)(n = 137)
NS
Male/female gender 163/108
(n = 271)
95/68 76/58 68/40 (n = 108) 87/50 (n = 137) NS
Current smoker 134 (45.9 %)
(n = 292)
72 (44.2 %)
(n = 162)
54 (40.3 %)
(n = 129)
60 (48.4 %) (n = 124) 78 (48.8 %)
(n = 152)
NS
History of smoking 271 (93.1 %)
(n = 291)
141 (93.3 %)
(n = 150)
123 (91.7 %)
(n = 129)
97 (69.4 %) (n = 107) 115 (71.8 %)
(n = 128)
NS
Diabetes 74 (25.2 %)
(n = 284)
43 (26.3 %)
(n = 161)
33 (24.6 %) 31 (23.6 %) (n = 123) 41 (25.6 %)
(n = 150)
NS
Cardiac disease 74 (26 %)
(n = 285)
43 (26.3 %)
(n = 162)
35 (26.1 %) 31 (25.2 %) (n = 123) 39 (25.8 %)
(n = 151)
NS
Lung disease 30 (10.2 %)
(n = 84)
17 (10.4 %)
(n = 162)
13 (9.7 %)
(n = 134)
13 (9.9 %) (n = 122) 17 (10.6 %)
(n = 150)
NS
eGFR NS
\60 55 (19.3 %) 30 (18.4 %) 25 (18.6 %) 25 (19.1 %) 30 (18.6 %)
[60 162 (55.1 %) 114 (69.9 %) 98 (73.1 %) 48 (36.6 %) 64 (40 %)
Unknown 77 19 11 58 66
Previous vascular
intervention
97 (34.2 %)
(n = 284)
51 (31.3 %)
(n = 160)
40 (29.9 %)
(n = 133)
46 (35.1 %) (n = 124) 57 (35.6 %)
(n = 151)
ABI at rest P\ 0.0001
\0.5 40 (13.6 %) 30 (18.4 %) 28 (20.9 %) 10 (7.6 %) 12 (7.5 %)
0.5–0.75 112 (38.1 %) 83 (50.9 %) 71 (53 %) 29 (22.1 %) 41 (25.6 %)
0.75–0.9 63 (21.4 %) 50 (30.7 %) 35 (26.1 %) 13 (9.9 %) 28 (17.5 %)
0.9–1.1 18 (6.1 %) 0 0 18 (13.7 %) 18 (11.3 %)
1.1–1.3 4 (1.4 %) 0 0 4 (3.1 %) 4 (2.5 %)
unknown 57 0 0 57 57
Affected legs NS
Unilateral 125 (42.5 %) 78 (47.9 %) 68 (50.7 %) 47 (35.9 %) 57 (35.6 %)
Bilateral 130 (44.2 %) 84 (51.5 %) 65 (48.5 %) 46 (35.1 %) 65 (40.6 %)
Unknown 39 1 1 38 38
Received treatment
Conservative / optimal
medical treatment
113 47 40 66 73
SET 141 93 73 48 68
Endovascular 17 10 9 7 8
Surgical treatment 23 13 12 10 11
Questionnaires
Follow-up time (days,
SD)
123 (27) 126 (26)
Baseline VascuQol score 4.25 (1.2) 4.26 (n = 119)a NS
Baseline WIQ score 0.39 (0.1) 0.42 (n = 120)a NS
Data displayed as number (percentage) or mean (standard deviation)
a Score was calculated in the number of patients that did sufficiently fill in the baseline questionnaire, but were excluded for not sufficiently
filling follow-up questionnaire
NS Not significant
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Figure 1 shows the proportion of patients with a
clinically relevant improvement or deterioration of their
HRQL on the VascuQol. This figure shows that 44 % of the
patients achieved a clinically meaningful improvement at
follow-up. A clinically meaningful deterioration is seen in
33 % of the patients.
Calculation of MID for the WIQ
Distribution of scores and details on MID calculation for
the WIQ are presented in Table 3. The correlation between
the anchor-question and the WIQ was 0.41, also meeting
the criteria of Revicki [17].
The MID values found were -0.03 and 0.11 for dete-
rioration and improvement, respectively. Interpretation of
the MIDs is similar to those of the VascuQol.
Figure 1 shows the proportion of patients that reached a
clinically relevant improvement or deterioration on the
WIQ. This figure shows that 57 % of the patients achieved
a clinically meaningful improvement at follow-up. A
clinically meaningful deterioration in walking impairment
was seen in 20 %.
Discussion
Outcomes that matter most to patients with IC are walking
capacity and HRQL. These can be assessed using PROMs,
which are common endpoints in trials, have the potential to
support clinical management of patients and can help
assess provider performance.
When interpreting changes in PROM scores there are
some important points to consider. While physicians have a
distinct idea which amount of change in clinical measures
such as blood pressure is relevant, interpretation of PROM
scores is less apparent. This is hampered even more by the
fact that many PROMs have different rating scales (e.g.,
0–1, 1–7, 1–100), making score changes incomparable.
Furthermore, it is important to realize that in larger sample
sizes the standard deviations of scores become smaller,
resulting in earlier significant findings than in a small
sample sizes. MID values indicate which amount of change
is considered relevant by patients. They can be applied
independent of sample size, and are thus useful in both
individual care and research. In individual care, caregivers
may decide to alter treatment strategy when after a certain
period a patient doesn’t meet a relevant improvement. In
research, a big advantage of applying MID values is that it
helps display the proportion of patients in a sample that
reaches a clinically relevant improvement. Concurrently, it
can display how many patients show a clinically relevant
deterioration despite treatment, as shown in Fig. 1. This
would have been missed when only comparing the mean
baseline score of the sample with the mean score after
treatment, since this would have probably resulted in a
positive mean change score, falsely indicating improve-
ment for all patients in the sample. While it was beyond the
scope of this paper, in future studies that compare treat-
ment modalities it may be insightful to compare the
Table 2 Distribution of scores and MID VascuQol
VascuQol (n = 163)
Baseline Follow up Mean change score Correlation with anchor-question
4.25 (1.20) 5.08 (1.28) 0.83 0.47
Anchor-question
N Mean change on VascuQol 95 % CI
Improved 97 1.23 (1.01–1.46)
Unchanged 43 0.55 (0.23–0.87)
Deteriorated 23 -0.36 (-0.74 to 0.01)
MID VascuQol
Improvement 0.87
Deterioration 0.23
Fig. 1 Proportion of patients that show a clinically relevant im-
provement and deterioration per PROM
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proportion of patients that reach a clinically relevant im-
provement and deterioration per treatment group.
We found a positive MID-value for the VascuQol for
deterioration. There are several explanations. It may be
attributed to a learning effect, i.e., patients who do not
improve (unchanged group) may still learn to fill in a
PROM more accurately by repetition, resulting in a higher
follow-up score, and thus a positive MID for deterioration.
Furthermore, the VascuQol is a disease-specific PROM, in
contrast to the anchor-question. Other conditions besides
claudication may prevail when patients rate their overall
condition. The VascuQol only takes into account the PAD-
related problems. Therefore, the mean PROM score may
increase, while the anchor-question is rated as unchanged.
MID values can be calculated for any PROM in any
patient population. Many different methods for calculation
exist. An overview can be found in the paper by Crosby
et al. [16] Generally, calculation methods are divided into
anchor-based approaches and distribution-based ap-
proaches. Anchor-based approaches determine the MID by
comparing PROMs to other measures or phenomena that
have clinical relevance. This can for example be an anchor-
question, as we have shown in this study. Distribution-
based approaches are based on statistical characteristics of
the PROM scores in a patient sample. While studies have
shown that values found in anchor-based and distribution-
based approaches are often comparable, in calculations
based on distribution-based approaches it is still not taken
into account which amount of change is considered rele-
vant by patients. Therefore, anchor-based approaches are
always preferred.
Our study has some limitations. First, the proportion of
patients that did not sufficiently complete the PROMs twice
was substantial. This is a well-known problem and not
exclusive to our study, but it should be considered when
applying PROMs, since it limits their overall use. Second,
to ensure that the study population was representative for
all IC patients, we intentionally excluded patients of un-
known age, gender, and/or ABI, which may have induced
bias. Yet, the included and excluded patients did not differ
in terms of baseline characteristics and PROM scores, and
despite excluding many patients an acceptable sample was
left for the MID analysis. Finally, we do not know how
many patients refused to participate in the pilot study, and
how this may have influenced MID values. Further studies
are required to overcome these potential biases.
Conclusion
We have calculated the MID values for two frequently used
PROMs for patients with IC. As demonstrated in this study,
the MID is a helpful tool to interpret the clinical relevance
of changes in PROM scores, which may be used in research
and individual care.
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Table 3 Distribution of scores and MID WIQ
WIQ (n = 134)
Baseline Follow up Mean change score Correlation with anchor-question
0.39 (0.24) 0.55 (0.28) 0.16 0.41
Anchor-question
N Mean change on WIQ 95 % CI
Improved 79 0.25 (0.19–0.3)
Unchanged 37 0.04 (-0.03 to 0.11)
Deteriorated 18 0.01 (-0.05 to 0.06)
MID WIQ
Improvement 0.11
Deterioration –0.03
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